Background: This prospective phase II clinical trial evaluated the efficacy and toxicity of cisplatin, oral tegafur-uracil, leucovorin, and mitomycin C in patients with recurrent or metastatic nasopharyngeal carcinoma.
What this study adds to the field
This prospective phase II trial evaluated the efficacy and toxicity of cisplatin, oral tegafur-uracil, leucovorin, and mitomycin C in NPC. Results showed that this regimen is acceptably effective and safe to be performed in outpatient clinics. This work provides an important information of new combination (PULM) to the treatment for mNPC patients.
Biomed J Vol. 36 No. 5 September -October 2013 N asopharyngeal carcinoma (NPC) is uncommon in the United States and Western Europe; however, is very prevalent in Southeast Asian countries, including Taiwan. The overall incidence of NPC is only around 0.7 cases per 100,000 population per year in the United States; however, is as high as 15-30 cases per 100,000 population per year in Hong Kong. [1] According to the cancer registry of Taiwan, NPC accounted for 2.02% of the cancer incidence with 1,558 incident cases in 2008. The crude incidence rates were 9.99 per 100,000 per year for men, and 3.47 per 100,000 per year for women. [2] Before 2008, many phase II clinical studies of chemotherapy for patients with recurrent or metastatic NPC demonstrated median response rates of approximately 45% to 80%, with median survival ranging from 7.2 to 15 months. [3] [4] [5] [6] [7] These active chemotherapeutic agents comprised of cisplatin, 5-fluorouracil (5-FU), doxorubicin, epirubicin, bleomycin, mitoxantrone, mitomycin C, taxanes, gemcitabine, cetuximab and sorafenib. [8] [9] [10] [11] [12] [13] [14] [15] [16] Among all of the combinations, cisplatin plus 5-FU is still the most commonly used regimen for NPC, because no phase III studies have found any other regimen to be superior. However, evidence showed that there is still a curative role for optimized chemotherapy combinations in patients with complete remission and in long-term survivors. [17] Tegafur-uracil (UFT, UFUR, TTY Biopharm Co. Ltd, Taipei, Taiwan) is an oral preparation combining tegafur (5-fluorouracil prodrug) and uracil in a 1:4 ratio. This chemotherapeutic agent has a low toxicity profile, is well tolerated by most patients, can be easily combined with other chemotherapeutic agents, and is convenient to administer in outpatient settings. [18] In gastrointestinal, lung, and breast cancers, Tegafur-uracil is often used as an alternative to 5-FU. [19] [20] [21] [22] In addition, we previously reported that a Tegafur-uracil-based chemotherapy regimen (cisplatin, Tegafur-uracil, leucovorin; PUL) was effective and less toxic for patients with head and neck squamous carcinoma (HNSCC). [23] Mitomycin C (M) is active in hypoxic circumstances and helps against tumor cells in the G0 phase. In recent studies, tumor hypoxia is found to be common in NPC, and is associated with disease progression and resistance to therapy. [24] Adding mitomycin C to a cisplatin-based chemotherapy regimen may help to overcome resistance conferred by hypoxia and eradicate tumor cells, even those that are not in the cell cycle. [16] Since NPC appears to be highly sensitive to chemotherapy as well as radiotherapy, [25] the non-overlapping toxicity profile of mitomycin C, cisplatin, and oral fluoropyrimidines warrants such a combination for NPC, especially for outpatient settings.
Therefore, we conducted this phase II trial to evaluate the efficacy and toxicity of cisplatin, Tegafur-uracil, leucovorin, and mitomycin C (PULM) as an outpatient chemotherapy regimen for patients with recurrent or metastatic NPC.
METHODS
Protocol of this prospective phase II clinical trial was approved by the institutional review board of the Chang Gung Memorial Hospital at Linkou and informed consent was obtained from all patients. From April 2002 to June 2005, we enrolled patients aged ≧ 18 and ≦ 70 years with histologically proven nonkeratinizing poorly-differentiated or undifferentiated nasopharyngeal carcinoma, as defined by the World Health Organization (WHO). Under the Fleming one stage design, the sample size was estimated to be 42 patients with alpha (0.05), power (0.90) and expected response rate of 69.5%. [26] All patients had Eastern Cooperative Oncology Group (ECOG) performance status scores ranging from 0 to 2, and recurrent or metastatic diseases that had not been treated by radiotherapy or surgery with curative intent. Previously concurrent chemo-radiotherapy regimens for local disease were allowed with the exception of oral Tegafur-uracil or mitomycin C exposure. None of the patients enrolled in this study had received chemotherapy or radiotherapy within 4 weeks of entry. All enrolled patients had at least one measurable recurrent or distant metastatic lesion. A measurable lesion was defined as one measuring 20 mm by conventional techniques or ≧ 10 mm by spiral computerized tomography scans in the longest dimension. Bone lesions are included for response evaluation in this trial because bone is the most common site of metastases of NPC. Prostate cancer project criteria were utilized in this trial for response evaluation of bone lesions. [27] Adequate bone marrow and organ function was defined as: (a) an absolute neutrophil count ≧ 1,500/μL; (b) a platelet count ≧ 100,000/μL; (c) a serum creatinine ≦ 1.5 times the upper limit of normal (ULN) or 24-hour creatinine clearance ≧ 60 ml/min; (d) total bilirubin ≦ 1.5 × ULN or ≦ 5.0 × ULN in patients with hepatic metastasis; and (e) serum aspartate aminotransferase and alanine transaminase ≦ 2.5 × ULN or ≦ 5.0 × ULN in patients with hepatic metastasis.
Exclusion criteria consisted of decompensated liver cirrhosis; clinically detectable peripheral neuropathy in Oxaliplatin Specific Neurological Scale grade ≧ 2; active cardiac disease within 6 months (e.g., angina, myocardial disease); active infection; history of another malignancy with the exception of successfully treated cervical or skin carcinoma; pregnancy or breast-feeding status; ongoing anticancer treatment; documented hypersensitivity to any component of the study drugs; and intestinal obstruction or malabsorption that may preclude absorption of Tegafur-uracil.
Eligible patients were treated with cisplatin, tegafur-uracil (UFUR), leucovorin, and mitomycin C (PULM regimen). Cisplatin 50 mg/m 2 was administered intrave-nously in 500 ml of 0.9% normal saline or 5% dextrose in 0.9% normal saline over 3 hours on day 1 and day 22. Oral Tegafur-uracil 300 mg/m 2 /day with oral leucovorin 60 mg/day was given on day 1-14 and day 22-35. Mitomycin C 6 mg/m 2 was administered intravenously on day 1 every 6 weeks, and did not exceed a total dose of 60 mg. Each course of therapy was defined as a 6-week treatment [ Figure 1 ].
In patients with a neutrophil count < 1500/μL or platelet count < 1 × 10 5 /μL on the day of scheduled chemotherapy, the treatment was postponed for a maximum of 4 weeks. Chemotherapy was discontinued if the neutrophil or platelet count did not recover. Tegafur-uracil was reduced by 50 mg/m 2 if any grade IV hematologic toxicity or grade III non-hematologic toxicity occurred. The protocol was completely stopped if a third dose reduction of Tegafur-uracil was needed.
Tumor response was evaluated every 2 courses (12 weeks) according to the Definition of Objective Response in Solid Tumors (WHO criteria). When partial response (PR) or complete remission (CR) was achieved, the results were confirmed by imaging study one month later. In patients with stable disease, the status was confirmed by an imaging study at a minimum interval of 2 courses from the entry of study. Ultrasound or computed tomography scans or magnetic resonance imaging scans and nasopharyngoscopy were performed whenever any sign or symptom suggestive of disease progression was noted. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. Treatment was discontinued if there was evidence of disease progression or unacceptable toxicity, or because of patient refusal or death from any cause.
Endpoints and survival analysis
The primary endpoint was response rate. Secondary endpoints were toxicity profile, time to tumor progression (TTP), duration of response, and overall survival (OS).
TTP was defined as survival without disease progression or death from any cause. It was calculated from the first day of PULM administration to the date of progression or most recent follow-up date. OS was calculated from the first day of PULM treatment to the date of death or most recent follow-up date. Likewise, duration of response was calculated from the date of best response proven by imaging studies to the date of documented disease progression. Follow-up time was defined as duration from enrollment to the date of the most recent follow-up or death. All data of survivors were updated in February, 2012. Descriptive statistics were used to report clinical characteristics. All events were counted according to the intention-to-treat principle. The duration of response, TTP, and OS were estimated using the Kaplan-Meier method.
RESULTS
Forty-six patients were originally designed to be enrolled in this trial; however, only 22 patients were enrolled during the study period due to slow recruitment. Table 1 summarized the clinical and pathologic characteristics. The median age was 47 years (range: 35-69 years) and Abbreviations: ECOG: Eastern cooperative oncology group; *Distant metastasis item "lung" comprises one pleura metastasis; † Distant metastasis item "lymph node" comprises one axillary and one mediastinal lymph node metastasis the male-to-female ratio was 2.67 (16:6) . Sixteen (72.7%) patients had undifferentiated carcinoma. The most common disease status was post-treatment distant recurrence (n = 10, 45.5%). The sites of distant metastasis were mainly at bone (n = 14, 63.6%) and liver (n = 13, 59.1%).
The regimen was generally well tolerated. The most common toxicities were grade III leucopenia in 6 (27.3%) patients, grade II neutropenia in 11 (50.0%) patients, and grade I thrombocytopenia in 16 (72.7%) patients. One (4.6%) patient experienced grade IV anorexia and two (9.1%) patients had grade IV vomiting. There was no treatment-related death in this trial [ Table 2 ]. Dose modification was required in 3 (13.6%) patients and one (4.6%) of them quitted the trial because of prolonged thrombocytopenia for more than 4 weeks.
All enrolled patients received the PULM regimen for a median duration of 5.1 months (range: 1.1-11.3 months). The median number of cycles was 2.5 (range: 1-7). The rate of compliance was high (20 of 22 patients; 91%). The two patients who did not comply with the scheduled treatments were due to personal reasons rather than toxicity. After a median follow-up of 17.3 months (range: 2.5-63.3 months), the best response achieved was complete response in 3 (13.6%) patients, partial response in 10 (45.5%) patients, and stable disease in 1 (4.6%) patient [ Table 3 ]. Among the responders, the median duration of response was 15.9 months (95% confidence interval [CI]: 3.9-27.8).
The median cycles of received chemotherapy between responders (n = 13) and non-responders (n = 9) were 5 and 2, respectively (p = 0.003). Responders were observed to be associated with a long duration of response (15.9 months) and a median survival time of 19.1 months. No significant difference in survival time was found between responders and non-responders. (p = 0.16). Subgroup analysis revealed that patients with initial metastasis tended to have better median TTP, OS, and duration of response than patients with recurrent distant metastasis. However, no statistical significance in those outcome variables was found (p = 0.224, 0.986 and 0.378, respectively; data not shown). The Kaplan-Meier survival curves for TTP and OS were shown in Figure 2 . Median TTP was 10.0 months (95% CI: 6.9-13.0) and median OS was 16.0 months (95% CI: 5.2-26.9). Long-term survival (> 60 months) was observed in 2 patients (9.1%) with disease-free status.
DISCUSSION
In this phase II trial, the overall response rate was 59.1%, the disease control rate was 63.6%, the median duration of response was 15.9 months, the median time to tumor progression was 10.0 months, and the overall survival rate was 16.0 months. Comparing to previous trials historically [ Table 4 ], [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] acceptable duration of response, response rates and OS were observed in this trial. Results of previous trials focusing on different chemotherapy regimens for treatment of recurrent or metastatic NPC showed variable ranges of treatment response. Conventional cisplatin-based regimens had response rates ranging from 45% to 80%; carboplatin-based regimens were shown to have response rates ranging from 30% to 75%; taxanes alone achieved rates ranging from 21.7% to 36.7%; and taxane-based combination regimens had response rates ranging from 27.5% to 86%. Gemcitabine plus platinum seemed to have a better response rate (63.6% to 86.0%) and overall survival (15.0-22.0 months) than other regimens; however, there is no head-to-head comparison data among these regimens to date. Targeted therapies are novel 
Hematologic Leucopenia 2 (9.1%) 9 (40.9%) 6 (27.3%) 0 (0.0%) Neutropenia 5 (22.7%) 11 (50.0%) 2 (9.1%) 0 (0.0%) Anemia 6 (27.3%) 9 (40.9%) 2 (9.1%) 0 (0.0%) Thrombocytopenia 16 (72.7%) 2 (9.1%) 1 (4.6%) 0 (0.0%) Gastrointestinal Anorexia 3 (13.6%) 1 (4.6%) 0 (0.0%) 0 (4.6%) Mucositis 2 (9.1%) 3 (13.6%) 2 (9.1%) 0 (0.0%) Nausea 7 (31.8%) 2 (9.1%) 2 (9.1%) 0 (0.0%) Vomiting 3 (13.6%) 3 (13.6%) 0 (0.0%) 0 (9.1%) Diarrhea 4 (18.2%) 1 (4.6%) 2 (9.1%) 0 (0.0%) Abbreviation: NCI-CTC: National cancer institute-common toxicity criteria; *The number in this table was calculated by severest events experienced by patients anti-cancer strategies; however, the response rates in those trials were quite low (40.7% for sorafenib alone and 11.7% for cetuximab plus carboplatin). Most disappointingly, no complete remission was achieved in those trials. [8, 14] A complete remission rate of 13.6% was noted in our trial whereas the average complete remission rate was approximately 7.0% in previous trials.
To the best of our knowledge, the duration of response in this study (15.9 months) was satisfactory compared historically to those in previous phase II trials (approximately 8 months). The plausible reason or mechanism is the anti-angiogenic effects of metronomic oral 5-FU, e.g., Tegafur-uracil or capecitabine, which have been widely discussed in many studies. In our study, results also showed statistically differences on total received cycles of chemotherapy between responders and non-responders (median cycles of 5 versus 2, respectively, p = 0.003 by Student t test). Responders to PULM regimen are found to be associated with a long duration of response (15.9 months) and survival time (19.1 months) . However, the differences (total chemotherapy cycles, survivals and duration of response) between responders and non-responders in this trial are still probably due to selection bias from responses; for instance, patients who got responses would keep going on further chemotherapy and other non-responders would stop treatment. On the other hands, there are emerging studies suggesting that long-term continuous administration of tegafur-uracil for cancer control can inhibit the development of feeding blood vessels to tumors, thereby suppressing tumor growth and prolonging the duration of response. [41] [42] [43] Similar results with prolonged TTP and OS have been obtained with oral capecitabine alone. [44] Cisplatin plus capecitabine has also been shown to be a safe, convenient, and well-tolerated regimen, although hand-foot syndrome is an annoying and common side effect. [45] Therefore, Tegafur-uracil-containing regimen might show the potential to maintain continuous tumor control with less skin toxicity.
Hematologic toxicity was a common but well-tolerated side effect in this trial. Three (13.64%) patients experienced grade IV toxicity with anorexia/vomiting; however, toxicity resolved after dose modification. Only one patient dropped out of the trial because of prolonged (> 4 weeks) grade I thrombocytopenia. But the patient had liver cirrhosis history and synchronous splenic metastasis, making it difficult to determine whether the thrombocytopenia was due to the regimen or was secondary to underlying cirrhosis and splenic involvement. In addition, some investigators claim that platinum-based triplets have significant toxicities and the possibility of increasing toxicities becomes an alarming problem when use of platinum-based triplets or regimens containing more than 3 drugs. [41, 46, 47] Hasbini et al., had ever reported the FMEP regimen (mitomycin C, 5-FU, epirubicin, and cisplatin) was reported to be associated with a high rate of toxicity as well as a mortality rate of 9%. [48] However, the dosages of mitomycin, cisplatin, and 5-FU in our trial were much lower than those used in studies that reported high rates of toxicity. The low dosages may explain why the toxicity in our trial was acceptable. Early dose modification or aggressive supportive management is needed to prevent severe morbidity.
However, few early withdrawals from this study were still found which needs to be proved not related to the toxicity of study drugs. After analysis, the main reasons for withdrawing from the study after one or two cycles of chemotherapy was patient's characteristics (3 poor compliances; 1 complete remission and request observation; 1 PR but with prolonged thrombocytopenia as previously mentioned). None of them was classified to be related to the toxicity after confirmation. Two (9.1%) long-term survivors (more than 5 years) were documented in our study. The only common therapy after chemotherapy with the PULM regimen was radiotherapy, which was delivered for persistent localized metastatic lesions with curative intent. One of the patients had left femoral head single bone metastasis; however, the PULM regimen followed by local radiotherapy did not lead to regression in size of the lesion. Long-term survival was achieved after surgical removal. The other patient initially presented with early-stage NPC and achieved complete response after local radiotherapy. Single liver metastasis was found 2 years later. The PULM regimen resulted in a complete response; however, liver recurrence occurred 3 years after achievement of complete response. The patient underwent local radiotherapy plus systemic chemotherapy with gemcitabine, which resulted in complete response. In long-term survivors, effective local plus systemic treatment for patients with metastatic NPC has been discussed in the literature. [17, 49] There is one limitation in our study: The small number of patient. The main cause is slow recruitment. Decrease of failure events after primary chemo-radiotherapy in NPC patients and improvement of radiotherapy techniques (e.g., Intensity-modification radiotherapy, IMRT) in recent years are thought to be related. Another cause is that there was one concurrent competing trial (Gemcitabine plus cisplatin) during enrollment, which urged physicians to enroll patients into another trial. The initial design of this trial was alpha (0.05) with power of 0.90 when study sample reaches 42 (patients); however, the power decreases to 0.7638 by Fleming one stage procedure [26] when the sample size was 22 (patients). Even though the power was not as significant as it was designed, the data still could provide evidence and help medical oncologists manage the efficacy, toxicities and limitations of PULM regimens in outpatient clinics.
In conclusion, the PULM regimen for patients with recurrent or metastatic NPC is an acceptable chemotherapy regimen in outpatient settings because of convenience and low toxic profile. We provide the results of this prospective phase II clinical trial for the evidence of PULM regimen, which demonstrated an overall response rate of 59.1% (including 13.6% complete remissions), a median duration of response of 15.9 months, progression-free of 10.0 months and overall survivals of 16.0 months.
